louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05618262: Evaluation of the Emergency Imaging Strategy for the Diagnostic Management of Renal Colic
Official title: Evaluation of the Emergency Imaging Strategy for the Diagnostic Management of Renal Colic
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Renal Colic
Keywords: Renal Colic
Nephritic Colic
Pyelocalic dilatation
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2022-11-16
Enrollment: 169
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Major subject (≥18 years) who was managed in the NHC emergency department from July 01, 2018 to June 30, 2019 with a final diagnosis of renal colic diagnostic

Brief summary: Emergency imaging is necessary for the diagnostic management of renal colic in the emergency department. Ultrasound is rapidly available and non-irradiating, allowing to look for a stone and a pyelocalic dilatation. But it is less sensitive when the stone is ureteral. CT has a sensitivity of 96% and a specificity of 100%. The latest French recommendations date from 2008, recommending ultrasound and an unprepared abdomen in cases of uncomplicated renal colic. For the European Society of Radiology, ultrasound should be the first-line examination. The place of a systematic CT scan as first-line examination for the diagnosis of renal colic in the emergency department is therefore still under discussion.

An evaluation of practice will make it possible to assess the imaging strategy applied in an emergency department.


Eligibility criteria: Inclusion criteria:

* Major subject (≥18 years)
* Subject who was managed in the NHC emergency department from July 01, 2018 to June 30, 2019 with a final diagnosis of renal colic diagnostic
* Subject who has not expressed opposition, after information, to the reuse of their data for the purpose of this research

Exclusion criteria:

* Subject who has expressed opposition to participating in the study
* Subject under guardianship or curatorship
* Subject under legal protection

Primary outcomes:
measure: Retrospective study of the practices of management of renal colic in the emergency room concerning the imaging strategy
timeFrame: Files analysed retrospectively from from July 01, 2018 to June 30, 2019 will be examined
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service d'accueil des urgences - CHU de Strasbourg - France
Study officials:
References:
Clinical trial NCT02806362: Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
Official title: An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease on Hemodialysis (GIFT-R)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Chronic Hepatitis C Virus
Keywords: Non-cirrhotic
End Stage Renal Disease (ESRD)
moderate fibrosis
Chronic Hepatitis C Virus ( HCV)
Chronic Hepatitis C Genotype 1b
Lead sponsor: AbbVie
Sponsor class: INDUSTRY
First posted: 2016-06-20
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this multicenter, single-arm, combination-drug study, which includes 12 weeks of treatment and 24 weeks of follow-up, is to evaluate the safety, efficacy and pharmacokinetics of ombitasvir/paritaprevir/ritonavir in Japanese adults infected with HCV GT1b, who are treatment-naïve or treatment-experienced to an IFN-based regimen and who have ESRD on HD.


Eligibility criteria: Inclusion Criteria:

* Females must be practicing specific forms of birth control on study treatment, or be post-menopausal for more than 2 years or surgically sterile
* Hepatitis C Virus (HCV) Ribonucleic acid (RNA) greater than 10,000 IU/mL at Screening
* Chronic HCV, Genotype (GT)1b infection
* Treatment-naive or treatment-experienced with an interferon (IFN)-containing regimen (IFN or pegylated-IFN with or without ribavirin).
* A fibrosis assessment test result equivalent to Metavir F0-F2.

Exclusion Criteria:

* Presence of Y93H variant at Screening
* Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human immunodeficiency virus antibody (HIV Ab)
* Significant liver disease with any cause other than chronic HCV infection
* On peritoneal dialysis
* On hemodialysis for more than 15 years

Primary outcomes:
measure: Percentage of participants achieving a 12-week sustained virologic response (SVR12).
timeFrame: 12 weeks after the last dose of study drug
Secondary outcomes:
measure: Percentage of participants with on-treatment virologic failure
timeFrame: Up to Week 12
measure: Percentage of participants with relapse
timeFrame: Up to 12 weeks after the last dose of study drug
Other outcomes:
Locations:
Study officials:
affiliation: AbbVie
name: Koji Kato, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00819962: Perioperative Analgesia Using Ultrasound (US) Guided Transversus Abdominis Plane (TAP) Block
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Postoperative Pain
Lead sponsor: King Saud University
Sponsor class: OTHER
First posted: 2009-01-09
Enrollment: 42
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: Perioperative analgesia using US guided TAP block

Detailed description: Perioperative analgesia using US guided TAP block

Eligibility criteria: Inclusion Criteria:

* adult undergoing laparoscopic cholecystectomy

Exclusion Criteria:

* history of cardiorespiratory disease

Primary outcomes:
measure: Pain relief
timeFrame: after US TAP block
Secondary outcomes:
Other outcomes:
Locations:
city: Riyadh
country: Saudi Arabia
facility: A Dawlatly
city: Riyadh
country: Saudi Arabia
facility: A Dawlatly
Study officials:
References:
Clinical trial NCT04439162: Antegrade and Retrograde Versurs Antegrade Cardioplegia in Complex Coronary Artery Bypass Surgeries
Official title: Results of Combined Antegrade and Retrograde Versurs Antegrade Cardioplegia in Complex Coronary Artery Bypass Surgeries
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Coronary Artery Disease Left Main
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2020-06-19
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: RCT
Primary purpose: SCREENING

Brief summary: During coronary artery bypass surgery, myocardial protection, especially of the right ventricle, may be inadequate in the presence of severe coronary lesions that obstruct the antegrade delivery of cold cardioplegia

Detailed description: Asymetric myocardial cooling has been reported to yield postoperative right ventricular dysfunction, which may contribute to postoperative morbidity and mortality. Retrograde coronary sinus perfusion was introduced in 1956 to facilitate surgery involving the aortic valve. This technique was introduced as a means of myocardial protection for coronary artery bypass surgery in 1967 and has recently received renewed interest. An innovative method of delivering retrograde cardioplegia through the right atrium was recently developed by Fabiani and associates. This technique has obviated the need to directly cannulate the coronary sinus and thus has eliminated concerns regarding coronary sinus rupture due to cannulation, and concerns of inadequate right ventricular perfusion. In contrast to antegrade delivery, retrograde delivery of cardioplegia through the right atrium is not subject to the problem of limited distribution in the presence of coronary artery occlusive disease and thus allows more uniform cooling of the left ventricle,so the study will compare the results of combined antegrade and retrograde versurs antegrade cardioplegia in complex coronary artery bypass surgeries

Eligibility criteria: Inclusion Criteria:

* Age between 18 and 60 years
* LV ejection fraction between 30 and 50%
* left main stem CAD
* mitral or aortic valve disease associated with ischemic heart disease

Exclusion Criteria:

* Double valve disease or other valve disease
* mitral or aortic valve disease associated with congenital heart disease
* patients subjected to prior heart surgery
* emergency operation
* poorly controlled diabetes mellitus

Primary outcomes:
measure: myocardial function
timeFrame: two years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00436462: Expression of Steroid Receptors in Endometrium
Official title: Expression of Steroid Receptors in Endometrium During the Early Follicular Phase in Stimulated Cycles
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Endometrium
Keywords: Steroid receptors
Endometrium
IVF
Follicular phase
Lead sponsor: Aristotle University Of Thessaloniki
Sponsor class: OTHER
First posted: 2007-02-19
Enrollment: 30
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: infertile women

Brief summary: Expression of steroid receptors in endometrium during ovarian stimulation.

Detailed description: The purpose of this study is to examine in stimulated cycles a) whether there is a difference in expression of steroid receptors in stroma and glands of endometrium between different days during the follicular phase b)whether there are secretory changes detected by endometrium histology before ovulation c)whether there is an association between expression of steroid receptors in endometrium and exposure to oestradiol and progesterone during the follicular phase.

Eligibility criteria: Inclusion Criteria:

* Treatment by IUI,
* BMI:18-29KGR/M2,
* No previous ovarian surgery,
* Normal hysterosalpingography,
* Estradiol \< 80pg/ml and progesterone \< 1.6ng/ml on day 2 of the cycle

Exclusion Criteria:

* Endometriosis,
* Severe male factor

Primary outcomes:
measure: Steroid receptors expression in endometrium during early follicular phase
timeFrame: 3 months
Secondary outcomes:
measure: In which day:day o+2, day 0+4 or day HCG
timeFrame: 1 month
Other outcomes:
Locations:
city: Thessaloniki
country: Greece
facility: Unit of Human Reproduction, 1st Department of Obstetrics & Gynecology, AUTH, Papageorgiou Hospital
Study officials:
affiliation: Unit of Human Reproduction, 1st Department of Obst & Gyn, Aristotle University of Thessaloniki, Papageorgiou Hospital, Greece
name: Basil C Tarlatzis, MD,PhD
role: STUDY_DIRECTOR
References:
citation: Kolibianakis E, Bourgain C, Albano C, Osmanagaoglu K, Smitz J, Van Steirteghem A, Devroey P. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril. 2002 Nov;78(5):1025-9. doi: 10.1016/s0015-0282(02)03323-x.
citation: Papanikolaou EG, Bourgain C, Kolibianakis E, Tournaye H, Devroey P. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes. Hum Reprod. 2005 Jun;20(6):1541-7. doi: 10.1093/humrep/deh793. Epub 2005 Feb 10.
Clinical trial NCT04829162: Weight Stigma by Association in Parent-Child Dyads
Official title: Weight Stigma by Association Among Parents of Children With Obesity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Childhood Obesity
Obesity
Keywords: childhood obesity
weight stigma by association
parenting
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
Collaborators: name: University of Michigan
First posted: 2021-04-02
Enrollment: 1973
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: We conducted a 2 (parent with versus without obesity) x 2 (child with versus without obesity) x 2 (daughter versus son) x 2 (mother versus father) between-subjects experiment. Participants were randomly assigned to one of 16 conditions. However, only five a priori hypotheses were tested.
Primary purpose: BASIC_SCIENCE

Brief summary: Parents of children with obesity report feeling blamed for their children's weight and reluctant to seek pediatric care after stigmatizing experiences. This "weight stigma by association" may have direct consequences for parents, children, and the parent-child relationship. The present study builds on qualitative evidence to experimentally test weight stigma and weight stigma by association in a parent-child relationship using a large, community-based sample. In an experiment conducted via an online survey, participants were randomly assigned to view a picture of a parent-child dyad, for which parent and child's gender (male vs. female) and weight status (with obesity vs. without obesity) were manipulated. Participants read identical general parenting descriptions that adhered to American Academy of Pediatrics parenting recommendations, then rated the parent's effectiveness, helpfulness, and caring.


Eligibility criteria: Inclusion Criteria:

* at least 18 years of age

Exclusion Criteria:

* Standard exclusion criteria were duplicate IP addresses, response times \< 60s or \> 3600s (the allotted time to complete the survey), or failure to complete the parenting questionnaire.

Primary outcomes:
measure: Parenting evaluation
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: UCLA
state: California
Study officials:
References:
Clinical trial NCT03852862: Double Regional Anesthesia in Video Assisted Thoracoscopy
Official title: Double Regional Anesthesia in Video Assisted Thoracoscopy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Video Assisted Thoracoscopy
Anesthesia
Lead sponsor: University Hospital, Rouen
Sponsor class: OTHER
First posted: 2019-02-25
Enrollment: 112
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Monocentric, randomized, controlled, single-blind study who's aim is to demonstrate the efficacy of the association of paravertebral block and serratus plane block with paravertebral block alone


Eligibility criteria: Inclusion Criteria:

* Patient aged 18 to 75 years;
* Programmed for unilateral videothoracoscopy for anatomical resection (segmentectomy, lobectomy);
* Subject affiliated to a social security scheme;
* Subject having signed an informed consent

Exclusion Criteria:

* Chronic treatment with opiates;
* Contraindication to administration of morphine;
* Allergy to local anesthetics or contraindications to the use of ropivacaine;
* Contraindication to the realization of paravertebral blocks and serratus;
* Pregnancy, breastfeeding;
* Severe obesity (BMI \> 40 kg/m²);
* Renal impairment (GFR \< 30 mL/min) or known severe hepatic impairment;
* Difficulties of comprehension preventing the collection of consent and the realization of the study;

Primary outcomes:
measure: Number of opioids drug administrated
timeFrame: 24 hours postoperatively
Secondary outcomes:
measure: Length of stay in recovery room
timeFrame: 24 hours postoperatively
measure: Total duration of hospitalization
timeFrame: during the 28 days postoperatively
Other outcomes:
Locations:
city: Rouen
country: France
facility: Rouen University Hospital
Study officials:
affiliation: University Hospital, Rouen
name: Marie-Melody DUSSEAUX, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00389662: The Effect of Wearing the 'Nike Free'Shoe on Isokinetic Muscle Strength of Foot and Ankle and on Proprioception.
Official title: The Effect of Wearing the 'Nike Free'Shoe on Isokinetic Muscle Strength of Foot and Ankle and on Proprioception.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: University Ghent
Sponsor class: OTHER
Collaborators: name: Nike
First posted: 2006-10-19
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: To evaluate the effect of wearing the 'Nike Free'Shoe on isokinetic muscle strength of foot and ankle and on proprioception the following protocol will be used.

The test population consists out of students of the physical education department. They will at random be divided in three groups. One group will wear the shoe only for daily activities, the second group will wear the shoes for the warming up part of the sport classes and the control group will not wear the shoe at all. There will be two moments for evaluation: one at the beginning of the study and one after four months, during which the shoe will be used. The isokinetic strength will be measured with an isokinetic device (Biodex) and the proprioception will be evaluated with a force platform (Neurocom Balance Master).


Eligibility criteria: Inclusion Criteria:

* being a physical education student of the second or third year
* having read and signed the informed consent
* being new to the Nike Free Shoe

Exclusion Criteria:

* neurological or systemic diseases
* overuse injuries or orthopaedic surgery to the lower limbs during the previous six months
* familiar to or used to wear the Nike Free Shoe

Primary outcomes:
measure: Isokinetic strength of foot and ankle muscles and on proprioception
timeFrame: 4 months after starting the data registration
Secondary outcomes:
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: University Ghent
Study officials:
affiliation: University Ghent
name: Philip Roosen, Physiotherapist
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01437462: Sevoflurane, Propofol, Postoperative Pain
Official title: Postoperative Pain After Propofol Sevoflurane Anaesthesia: a Prospective, Randomized, Single-blinded Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Healthy Adults
Gynecological Disease
Keywords: Pain, Postoperative
Anesthetics, intravenous
Anesthetics, inhalation
Otherwise healthy adults undergoing general anesthesia for gynecological disease.
Lead sponsor: Tampere University Hospital
Sponsor class: OTHER
First posted: 2011-09-21
Enrollment: 168
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The impact of anaesthetic method (intravenous vs. inhalational) has been proposed, but not proven in a large-scale study. The researchers aim to provide an investigation that has sufficient power to clarify the potential effect of anaesthetic method on postoperative need of opioids. Sevoflurane and propofol will be compared.


Eligibility criteria: Inclusion Criteria:

* Age 18-69 years
* Gender: female
* ASA status 1-3
* Laparoscopic hysterectomy

Exclusion Criteria:

* Body Mass Index over 35
* Diabetes mellitus
* Liver disease
* Allergies to pharmaceuticals used in the Study
* Present use of opioids

Primary outcomes:
measure: Postoperative consumption of an opioid (oxycodone)
timeFrame: 20 hours
Secondary outcomes:
measure: NRS (numeral rating scale) of pain
timeFrame: 20 hours
Other outcomes:
Locations:
city: Tampere
country: Finland
facility: Tampere University Hospital
Study officials:
References:
Clinical trial NCT06962462: Daily Tadalafil in Diabetic ED Patients
Official title: Effect of Daily Tadalafil Therapy on Endothelin-1 and E-Selectin in Diabetic Patients With Erectile Dysfunction
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Erectile Dysfunction Associated With Type 2 Diabetes Mellitus
Keywords: Tadalafil, Endothelin-1, E-selectin, Diabetic complications, Sexual dysfunction, ELISA
Lead sponsor: South Valley University
Sponsor class: OTHER
First posted: 2025-05-08
Enrollment: 60
Sex: MALE
Minimum age (years): 30
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates the effect of 5 mg daily tadalafil therapy on serum levels of Endothelin-1 and E-selectin in diabetic male patients with erectile dysfunction. Outcomes will be compared pre- and post-treatment versus healthy controls.


Eligibility criteria: Inclusion Criteria:

Male patients aged between 30 and 60 yearsز Diagnosed with diabetes mellitus Suffering from erectile dysfunction No history of hypertension or other systemic diseases

Exclusion Criteria:

History of pelvic trauma or major pelvic surgery Pacientes con hipogonadismo o hiperprolactinemia Chronic liver disease or cardiovascular disorders Chronic use of central nervous system drugs, anti-androgenic drugs, or Tramadol Smokers Non-vasculogenic erectile dysfunction Known allergy to tadalafil

Primary outcomes:
measure: Effect of tadalafil 5 mg on serum levels of Endothelin-1 and E-selectin
timeFrame: 3 months after intervention
Secondary outcomes:
measure: Biochemical assessment of serum Endothelin-1 and E-selectin levels
timeFrame: 3 months after intervention
Other outcomes:
Locations:
Study officials:
affiliation: Faculty of Medicine, South Valley University
name: Abdelmawgoud, M.Sc
role: PRINCIPAL_INVESTIGATOR
References: